atopic dermatitis - Search News

News

Nektar, Atopic Dermatitis and Drug Trial

NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis Study

Nektar Therapeutics NKTR announced that the phase IIb REZOLVE-AD study evaluating its lead pipeline candidate, rezpegaldesleukin (rezpeg), in patients with moderate-to-severe atopic dermatitis, met its primary and key secondary endpoints.

MarketWatch · 2d

Nektar Stock Soars Ahead of Dermatitis Drug Study Data

Shares of Nektar Therapeutics soared after the company said it would release topline data from a study of its atopic dermatitis treatment rezpegaldesleukin. The stock was up 31% at $12.49 in Monday's after-market trading.

Investopedia on MSN · 1d

Nektar Therapeutics Stock Doubles After Promising Eczema Drug Trial Results

KEY TAKEAWAYS Shares of Nektar Therapeutics doubled in early trading Tuesday after the U.S. biotech firm said it reached its targets in a midstage study of its eczema treatment.The biotech firm said the global Phase 2b REZOLVE-AD study conducted in 393 patients with moderate-to-severe atopic dermatitis achieved successful results after three

BioSpace18h

Nektar Declares Phase IIb Eczema Win for Rezpeg—But Analysts Unconvinced

Despite Nektar’s share price shooting up as much as 175% on Tuesday, William Blair maintained that “there is an absence of ...

New Atlas1d

New eczema treatment provides relief in Phase 2 human trials

A new immune-modulating treatment has shown promising results for treating moderate to severe eczema, delivering fast itch ...

Nektar Therapeutics Is Up 150%: What’s Happening With NKTR Stock?

NKTR stock is up around 150% in today’s trading session following the recently announced positive results from its Phase 2b ...

Healio21h

Air pollutants, climate change factors may drive atopic dermatitis disease activity

Ambient air pollution, hot and cold temperature extremes and other factors associated with climate change are likely ...

Medical Dialogues1d

Atopic Dermatitis Linked to Shorter Stature in Young Children, Finds Research

USA: Researchers have discovered in a new study that young children with moderate-to-severe atopic dermatitis (AD) tend to be ...

19h

Why Is Nektar Therapeutics Stock Trading Higher On Wednesday?

Nektar's rezpegaldesleukin met key efficacy targets in a mid-stage eczema study, though analysts flagged safety and differentiation concerns.

MedPage Today on MSN7d

Dupilumab for Atopic Dermatitis Linked to Increased Risk of Psoriasis

Key findings of subgroup analyses included an observed increased psoriasis risk in patients without atopic comorbidities (HR 1.42, 95% CI 1.06-1.89) and those with pretreatment immunoglobulin E (IgE) ...

Medical Dialogues2d

Dupilumab used for atopic dermatitis Linked to Increased Risk of Psoriasis: JAMA

A new study published in the Journal of American Medical Association showed that dupilumab (Dupixent), used for treating ...

Nektar Therapeutics Shares Double On Promising Eczema Drug Data

Nektar reported positive Phase 2b trial data for rezpegaldesleukin in atopic dermatitis, showing strong efficacy and a ...

2don MSN

Nektar surges as lead asset succeeds in mid-stage trial for eczema

Nektar Therapeutics (NASDAQ:NKTR) announced Tuesday that its lead asset, rezpegaldesleukin, reached the main goal in a ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results